Sanderling Ventures

Investor type Micro VC
Founders Robert McNeil

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 96
Average round size
info
The average size of a deal this fund participated in
$19M
Portfolio companies 42
Rounds per year 2.23
Lead investments 15
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.56
Exits 17
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Medical Device
Summary

Sanderling Ventures appeared to be the VC, which was created in 1979. The leading representative office of defined VC is situated in the San Mateo. The venture was found in North America in United States.

The fund has exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight CalciMedica, Metavention, Lineagen. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Genetics, Biopharma.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Comparing to the other companies, this Sanderling Ventures performs on 14 percentage points less the average number of lead investments. The real fund results show that this VC is 1 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2008. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2011. The typical startup value when the investment from Sanderling Ventures is 100-500 millions dollars.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Sanderling Ventures, startups are often financed by Asset Management Ventures (AMV), Qualcomm Ventures, Mesa Verde Venture Partners. The meaningful sponsors for the fund in investment in the same round are Alta Partners, Mayo Clinic Ventures, Asset Management Ventures (AMV). In the next rounds fund is usually obtained by Qualcomm Ventures, Mayo Clinic Ventures, Intel Capital.

The fund was created by Robert McNeil. We also calculated 5 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sanderling Ventures:
Typical Co-investors
Sanderling Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sanderling Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Amelia Investments -
AshHill Biomedical Cincinnati, Ohio, United States
BAE Systems Farnborough, Hampshire, United Kingdom
Careismatic Brands California, Chatsworth, United States
Cherry Tree Investments California, Los Angeles, United States
Draper Cambridge, Massachusetts, United States
EXPERT DOJO California, Santa Monica, United States
Kempen & Co Amsterdam, Noord-Holland, The Netherlands
LVMH Luxury Ventures France, Ile-de-France, Paris
MB Venture Partners Memphis, Tennessee, United States
Movistar Community of Madrid, Madrid, Spain
Netmarble Seoul, Seoul-t'ukpyolsi, South Korea
Next News Ventures New York, New York, United States
NREP -
Shinkin Capital Japan, Tokyo
Successful Ventures Barcelona, Catalonia, Spain
Theodorus III -
Wenzhou Dongchuang Xinhui -
Xiamen Torch Group Co China, Fujian, Xiamen
Yakumi Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Glycomine

Biotechnology
Pharmaceutical
Therapeutics
$35M23 Jun 2021 San Francisco, California, United States

ViaCyte

Biotechnology
Diabetes
Drug Discovery
Health Care
Medical
Therapeutics
$53M22 Apr 2021 San Diego, California, United States

CalciMedica

Health Care
Information Technology
Life Science
$21M11 Mar 2021 San Diego, California, United States

CalciMedica

Health Care
Information Technology
Life Science
$15M22 May 2020 San Diego, California, United States

ViaCyte

Biotechnology
Diabetes
Drug Discovery
Health Care
Medical
Therapeutics
$32M20 Mar 2020 San Diego, California, United States

Glycomine

Biotechnology
Pharmaceutical
Therapeutics
$33M07 Aug 2019 San Francisco, California, United States

ViaCyte

Biotechnology
Diabetes
Drug Discovery
Health Care
Medical
Therapeutics
$80M29 Nov 2018 San Diego, California, United States

Metavention

Biotechnology
Diabetes
Health Care
$65M08 Jan 2018 Minnesota, United States

SpecificiT Pharma

Biotechnology
Health Care
Pharmaceutical
11 Sep 2017 Montreal, Quebec, Canada
News
ViaCyte Raises $45M in Funding

– ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding.
– The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.
– The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sanderling Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: